
CDIB Capital
Description
CDIB Capital International Corporation (CDIB Capital) functions as the overseas investment arm of China Development Financial (CDF), a prominent financial services conglomerate based in Taiwan. The firm is a significant player in the private equity landscape, managing an impressive portfolio of over US$2.5 billion in assets across various dedicated private equity funds. CDIB Capital's investment philosophy is primarily centered on growth capital, buyouts, and special situations, targeting companies with strong potential for expansion and value creation.
The firm demonstrates a broad sectoral interest, with investments spanning technology, healthcare, consumer goods, and industrials. Geographically, CDIB Capital maintains a robust presence across Asia, particularly within Greater China, while also extending its investment activities to North America and Europe, showcasing a global reach. This diversified approach allows them to capitalize on opportunities across different markets and industries.
CDIB Capital leverages CDF's extensive network and resources, which contributes to its long and successful track record in identifying and executing strategic investments. For instance, in 2018, the firm successfully closed its CDIB Capital Asia Partners L.P. fund with total commitments of US$550 million, specifically earmarked for growth capital and buyout opportunities across Asia. This fund exemplifies their commitment to significant, later-stage investments. Their typical first check sizes reflect this strategy, generally ranging from approximately US$20 million for substantial growth equity rounds to around US$80 million for larger buyout or significant co-investment opportunities.
Investor Profile
CDIB Capital has backed more than 20 startups, with 1 new investments in the last 12 months alone. The firm has led 5 rounds, about 25% of its total and boasts 7 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Seed rounds (top funding stages).
- Majority of deals are located in United States, China, Taiwan.
- Strong thematic focus on Artificial Intelligence (AI), Biotechnology, Health Care.
- Typical check size: $20M – $80M.
Stage Focus
- Series B (45%)
- Series C (20%)
- Seed (10%)
- Series D (10%)
- Series Unknown (5%)
- Series A (5%)
- Private Equity (5%)
Country Focus
- United States (55%)
- China (15%)
- Taiwan (10%)
- Israel (5%)
- United Kingdom (5%)
- Singapore (5%)
- Japan (5%)
Industry Focus
- Artificial Intelligence (Ai)
- Biotechnology
- Health Care
- Software
- Machine Learning
- Bitcoin
- Cryptocurrency
- Financial Services
- Fintech
- E-commerce
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.